================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 8, 2007
Critical Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware 000-50767 04-3523569
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
60 Westview Street, Lexington, Massachusetts 02421
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (781) 402-5700
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
Item 2.02. Results of Operations and Financial Condition.
On November 8, 2007, Critical Therapeutics, Inc. (the "Company") announced its
financial results for the three months and nine months ended September 30, 2007.
The Company also announced that it is in the process of reviewing a range of
strategic alternatives that could result in potential changes to the Company's
current business strategy and future operations. The full text of the press
release issued in connection with the announcement is attached as Exhibit 99.1
to this Current Report on Form 8-K.
The information in this Form 8-K, including Exhibit 99.1 attached hereto, shall
not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing by the Company under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such a
filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
See Exhibit Index attached hereto.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: November 8, 2007 CRITICAL THERAPEUTICS, INC.
By: /s/ Frank E. Thomas
-------------------------------------
Frank E. Thomas
President and Chief Executive Officer
EXHIBIT INDEX
Exhibit No. Description
------------- ---------------------------------------------------------------
99.1 Press release dated November 8, 2007.